Nested Knowledge presents poster at the 2019 annual conference of the Society of Vascular and Interventional Neurology
ST. PAUL, MN: February 3, 2020 – Nested Knowledge, a medical data analytics company that visualizes research data from primary studies in a dynamic and interactive format, presented its research on novel, comprehensive meta-analytic software presentation strategies for stroke therapies at the annual conference of the Society of Vascular and Interventional Neurology between November 20th-23rd, 2019 at Atlanta, GA. This first scientific presentation of our novel interactive visualization strategies represents the most-updated meta-analysis of acute ischemic stroke interventional therapies, and provides proof of concept for the novel strategies used in presenting meta-analytical data.
The poster by Nested Knowledge presented its the network meta-analysis comparing therapies and associated outcomes for acute ischemic stroke in a “nest,” which is a consolidation of information on a given disease state and therapy that is both comprehensive and updatable. Researchers analyzed data from 54 stroke therapy comparison studies with 16,159 patients to confirm that stent retrievers had better odds of good outcome (modified Rankin scale mRS 0-2) and lower chances of mortality than thrombolytic techniques. Thombolysis also had lower chances of achieving full reperfusion of blood flow (Modified treatment in cerebral ischemia (mTICI) score pf 2b/3) in comparison with aspiration, stent retrievers and combination techniques. Most notably, the full, interactive platform described in this poster—unlike with conventional meta-analyses—is presented online and updated periodically by Nested Knowledge, along with full methods, making this a living meta-analysis of stroke therapies. The research was presented in association with Superior Medical Experts, a medical writing company based in St. Paul.
About Nested Knowledge:
Nested Knowledge is a medical publishing and analytics company whose primary activity is providing and iteratively improving a platform that presents scientific research from thousands of primary clinical studies in a dynamic, updatable, interactive visual interface. Our software uses specialized algorithms to complete searches, facilitate data gathering from studies, quality-control inputs, and organize data into structured and updateable visuals in partnership with leading research organizations. Our vision is to gather all clinical outcomes data in a single, central system of record and enable treatment, regulatory, insurance, investment, and R&D decisions to be driven by comprehensive, evidence-based analysis in this centralized platform.
More information on the poster can be found on Page 92 of the SVIN website here.
President, Nested Knowledge
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, the Company’s plans, strategies and prospects for its business. All statements, other than statements of historical facts, contained in this press release, including statements regarding the Company’s strategy, future operations, future financial position, prospects, plans and objectives of management, are forward-looking statements. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in, or implied by, such forward-looking statements. These risks and uncertainties include, but are not limited to, risks associated with the Company’s ability to: achieve development objectives; meet internal or external quality control goals; continue to provide its current platform or any existing capabilities; advance any development, research, or business objective under the timelines currently anticipated, or at all; obtain, maintain, or protect intellectual property rights related to its products; manage expenses; and raise the substantial additional capital needed to achieve its business objectives. In addition, the forward-looking statements included in this press release represent the Company’s views as of the date hereof and should not be relied upon as representing the Company’s views as of any date subsequent to the date hereof. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so.